Mitral Annular Calcification and Thromboembolic Risk

Autor: Paula Cristina Morariu, Daniela Maria Tanase, Diana Elena Iov, Oana Sîrbu, Alexandru Florinel Oancea, Cornel Gabriel Mircea, Cristina Petronela Chiriac, Genoveva Livia Baroi, Ionela-Daniela Morariu, Cristina Gena Dascălu, Laurenţiu Şorodoc, Mariana Floria
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Life, Vol 13, Iss 7, p 1568 (2023)
Druh dokumentu: article
ISSN: 2075-1729
DOI: 10.3390/life13071568
Popis: Thromboembolic (TE) risk scores used for atrial fibrillation (AF) patients do not include mitral annular calcification (MAC) as a potential indicator of vascular disease. This research evaluated the correlation between MAC and TE risk scores (CHADS2 and CHA2DS2-VASc). We compared TE risk score values and clinical and echocardiographic data in patients with and without MAC. We included, prospectively, 103 patients: 40.8% with AF, 83.5% with hypertension, 30.1% with type II diabetes mellitus, 79.6% with chronic heart failure, and 7.8% with a history of stroke. We identified MAC in 50.5% of patients. The mean CHADS2 and CHA2DS2-VASc scores were 2.56 ± 1.135 and 4.57 ± 1.61, respectively. In MAC patients, both scores tended to increase significantly compared with the control (2.88 ± 1.114 versus 2.24 ± 1.06, p = 0.005, and 5.21 ± 1.51 versus 3.92 ± 1.46, p < 0.001, respectively). The left ventricular ejection fraction negatively correlated with the presence of MAC (r = −0.254, p = 0.01). The presence of MAC was a risk factor for vascular disease (OR = 2.47, χ2 = 34.32, p < 0001). Conclusions: The presence of MAC is associated with greater TE risk scores and a higher risk of vascular disease. It appears that adding MAC as a vascular disease parameter to TE risk scores may have benefits for patients by improving their predictive value.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje